Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Age \> 18 years old~* HIV-2 Infection (confirmed by DetermineTM \& Immunocomb II)~* ARV-naïve~* CD4 count \< 750 cells/mm3 and/or WHO Stage 3 or 4 disease~* Anticipate residing in Dakar area for duration of study~Exclusion Criteria:~* Pregnancy or Breast feeding~* HIV-1 or HIV-1/HIV-2 dual infection~* Known allergy or contraindication to Elvitegravir, Cobicistat, Emtricitabine, or Tenofovir DF~* Active Tuberculosis (STRIBILD contraindicated with rifampin)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open label prospective single arm study of Stribild (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).